United States: HSR Act Rules Expand For Pharmaceutical Licensing Agreements

Last Updated: November 8 2013
Article by Harry T. Robins and David R. Brenneman

Rules from the Federal Trade Commission include new requirements for reporting pharmaceutical patent transfers.

On November 6, the Federal Trade Commission (FTC) released finalized amendments to the premerger notification rules (the Rule), which clarify when the transfer of pharmaceutical (including biological) patent rights is reportable to the FTC as an asset sale under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR Act).[1] The finalized Rule did not alter the proposed Rule, which was initially released by the FTC for public comment in August 2012. As a result of the rule change, any transfer of exclusive pharmaceutical patent rights is potentially reportable under the HSR Act, even when the patent owner retains certain manufacturing rights or certain "co-rights"—generally rights to co-develop or co-market the pharmaceutical product.

The Rule will go into effect 30 days after its publication in the Federal Register, which should be imminent. Deals that are expected to close following the effective date and that are reportable under the Rule will require HSR Act approval prior to closing.

The Rule at a Glance

Under the Rule, a license or other transfer of pharmaceutical patent rights will be potentially reportable under the HSR Act if the patent owner transfers all "commercially significant rights" to a patent, meaning the transfer of exclusive patent rights to the licensee or transferee where only the licensee or transferee is allowed to use the patent in a particular therapeutic area (e.g., neurological use) or specific indication within a therapeutic area (e.g., Alzheimer's disease within the neurological therapeutic area). This transfer will be potentially reportable even if (i) either the patent owner alone or both the patent owner and licensee/transferee have the right to manufacture the product covered by the patent being transferred solely for the transferee/licensee or (ii) the patent owner retains "co-rights" to develop and commercialize the product covered under the patent (e.g., through co-development and co-commercialization agreements).

For such arrangements to be deemed reportable, however, the proposed transaction would still need to meet the size-of-person and size-of-transaction thresholds established by the HSR Act. Early-stage pharmaceutical collaboration arrangements often are not reportable under the HSR Act because one party fails to meet the $14.2 million (adjusted annually) size-of-person test or because the fair market value of the license at issue does not exceed the above $70.9 million (adjusted annually) size-of-transaction test. (There are complex rules regarding valuing payments contemplated by such collaborations, but often many of the later-stage milestone payments—e.g., payments triggered by advancing to a new stage in the Food and Drug Administration process, filing the new drug application, or payments of commercial royalties—can be discounted to zero due to the uncertainty of the milestone ever being reached.)

FTC Objectives

The FTC's objectives in enacting the Rule were threefold: (i) the Rule closes a perceived HSR Act loophole that previously applied when a licensor/transferor retained manufacturing rights; (ii) the Rule facilitates the FTC's HSR Act preclosing review of developmental-stage pharmaceutical product collaborations that may involve potential competitors; and (iii) the Rule simplifies a body of complex Premerger Notification Office (PNO) interpretations surrounding the reportability of pharmaceutical transfer arrangements under the HSR Act.

Previously, under the PNO's informal precedent, pharmaceutical patent transfers were generally exempt from the HSR Act if the patent owner retained the right to manufacture the underlying product, even if solely for sale to the licensee or transferee. The PNO viewed these arrangements as nonreportable distribution agreements rather than potentially reportable asset acquisitions.

The FTC had concerns that pharmaceutical companies engaged in product development could transfer to rivals all commercially significant patent rights to an underlying pipeline product, thereby potentially eliminating possible competition between the parties in the event that the licensee/transferee already owned a competing marketed or pipeline product. Following the PNO's informal guidance, parties could close these transactions without waiting for HSR Act approval simply by having the licensor/transferor retain manufacturing rights to the underlying product for the licensee/transferee.

Although such transactions are uncommon due to the uncertainty of whether a pipeline product will ever launch as well as the low probability that a licensee already has a directly competing pipeline or marketed product, these transactions do occur and raise substantive antitrust concerns. For example, in June 2013, Questcor Pharmaceuticals, which markets a drug used to treat various immune-related ailments, acquired the exclusive rights to a drug from another pharmaceutical company in the same field. The drug had not yet been marketed in the United States, and the value of the transaction, valued at $135 million, exceeded the HSR Act threshold. The licensor, however, retained the rights to manufacture the rival product, which made the license transfer exempt from the HSR Act. This type of transaction, which some observers suggested might eliminate Questcor's only potential competitive entrant into the United States, was one of the motivations for the FTC's introduction of the new Rule.

Licensor's Retention of "Co-Rights"

The Rule does not change the PNO's long-held position that exclusive patent transfers are potentially reportable even when the transferor/licensor retains certain "co-rights" to co-develop and co-commercialize the exclusively licensed patent. Parties to exclusive license agreements sometimes set forth the terms of each party's participation in the development and commercialization of the exclusively licensed patent through ancillary co-development and co-commercialization agreements.

The FTC contends that these "co-rights" granted to or retained by a licensor do not render the license nonexclusive for HSR Act purposes. Instead, the "co-rights" merely reflect the licensor's efforts to support development, sales, and marketing in order to maximize its future royalty stream, and the rights do not change the fact that the licensee/transferee will still acquire the exclusive right to commercially use a patent. Accordingly, the retention of these "co-rights" would still render the transaction HSR Act reportable.

Co-Exclusive License Agreements

The FTC did not explain in the Proposed Rule whether co-exclusive licenses, in which both the licensor and licensee share equally the IP rights in the patent, are still non-HSR Act reportable, as addressed in several PNO informal opinions.[2] Because the licensor in a co-exclusive license agreement would necessarily retain "co-rights" to the patent, practitioners expressed confusion regarding whether co-exclusive licenses would be deemed "co-rights" under the final Rule, making such co-exclusive licenses potentially HSR Act reportable.

In the final Rule's Statement of Basis and Purpose, the FTC clarified that co-exclusive license grants are not HSR Act reportable and are distinguishable from "co-rights." The FTC explained that, in an exclusive license arrangement, the licensor grants the licensee rights to a patent (or part of a patent) "to the exclusion of all others, including the licensor." Although the grant of an exclusive license is potentially HSR Act reportable even when the licensor retains certain "co-rights" (e.g., through ancillary co-development/commercialization agreements), the grant of a co-exclusive license is not HSR Act reportable.

Examples of HSR Act Applicability

  • Retention of Co-Rights and Limited Manufacturing Rights: Licensor owns a patent that will be used in a forthcoming product indicated to treat heart disease and brain disease. Licensor grants Licensee an exclusive license to develop and commercialize the patent but only for use in the heart disease therapeutic area. Licensor retains the right to manufacture the forthcoming heart disease product for Licensee only. Licensor and Licensee enter into ancillary co-developmental and co-commercialization agreements, pursuant to which the two parties will share certain developmental and marketing responsibilities for the forthcoming heart disease product. Licensee will book the sales of the biological patent and will pay Licensor royalties.
    HSR Act Applicability Under the Rule: The transaction is potentially HSR Act reportable under the Rule, despite Licensor's retention of "co-rights," limited manufacturing rights, and rights to use the patent in other therapeutic areas.
  • Grant of Co-License to Pharmaceutical Patent: Company A owns the patent rights to Molecule A. Company B owns the patent rights to Molecule B. Company A and Company B seek to collaboratively develop, commercialize, and co-promote certain pharmaceutical products that will use Molecules A and B. To facilitate this collaboration, Company A and Company B will grant each other co-exclusive licenses to the underlying patents to develop and commercialize Molecule A and Molecule B. Each party will pay the other party up-front payments and royalties related to the co-exclusive patent rights.
    HSR Act Applicability Under the Rule: Both currently and under the new Rule, no HSR Act filing is required because neither party is granting the other party exclusive patent rights.

[1]. View the final Rule here.

[2]. See, e.g., Informal Opinion 0806009, available here.

Copyright 2013. Morgan, Lewis & Bockius LLP. All Rights Reserved.

This article is provided as a general informational service and it should not be construed as imparting legal advice on any specific matter.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.